Skip to content
thestock.space

On 6 Nov 2026, Unichem Laboratories was priced at ₹501.70, or 11.6× trailing earnings, against an industry P/E of 28.7×, and the shares are 27% below their 52-week high. Its ROCE of 11% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales grew 18% a year over 3 years, though net profit is above operating profit, which points to a one-off gain. Debt is 0.18× equity. It is a small-cap company with a market cap of ₹3,532 Cr, ranked 51st of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 5.5% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹485.55
Day high
₹513.00
Day low
₹485.00
Prev. close
₹493.30
Volume
84K

Health check

2 good · 3 to check
  • ReturnsBehind

    +5.5% over a year, better than 1 of 7 peers.

  • Price tagDistorted

    A one-off gain inflates profit, so P/E isn’t comparable right now.

  • GrowthStrong

    Sales +18.4% a year over 3 years.

  • ProfitabilityWeak

    ROCE 11.4% vs peer median 17.9%.

  • Balance sheetSolid

    Debt 0.18× equity, interest covered 10.3×, Piotroski 6 of 9.

  • Red flags1 to check

    Net profit is above operating profit, so a one-off gain is likely flattering earnings.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹3,532 Cr, #51 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹2,372 Cr · profit ₹339 Cr
Market cap
₹3,532 Cr
Small cap
P/E
11.6
Industry 28.7
Price to book
1.27
Peers 4.99
Dividend yield
0.00%
ROE
13.0%
Peers 14.7%
ROCE
11.4%
Peers 17.9%
Debt to equity
0.18
Debt ₹498 Cr
EPS (TTM)
₹43.22
Face value ₹2
OPM (TTM)
8.3%
Net margin 14.3%
Sales growth
+20.1%
Latest quarter vs a year ago
Profit growth
n/a
Year-ago quarter not reported
Price to sales
1.49
EV/EBITDA 16.1

Strengths and risks

Strengths

  • Quarterly sales up 20.1% on a year ago.

Risks to check

  • Net profit is above operating profit, so a one-off gain is likely flattering earnings.

Derived automatically from reported figures. Not a recommendation.

About Unichem Laboratories

Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in Asia, Europe, Africa, CIS, the United States, and internationally. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract…

Headquarters
Mumbai
Employees
2,780
Sector
Healthcare
ISIN
INE351A01035
Website
unichemlabs.com

Price range

52 weeks

₹278.20₹687.20

Today

₹485.00₹513.00
Avg volume (3M)
2.4 L
1-year return
plus 5.5%
From 52-week high
minus 27.0%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
UNICHEMLABUnichem Laboratories501.70plus 1.70%3,53211.61.2711.4%9.8%9.9%18.4%–0.00%plus 5.5%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
527579521575633
504550476527563
22.528.944.847.769.9
4.3%5.0%8.6%8.3%11.1%
6.858.311.823.515.6
6.58.27.49.46.6
31.831.531.330.629.9
–−58.3276−12.4–
−9−10.829318.849
−16.1%−9.9%9.9%41.9%15.4%
−10.5−11.926410.941.5
-1.49-1.6937.471.555.89

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+18.4%
ROE
13.0%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1,3021,7382,0642,159
–+33.4%+18.8%+4.6%
1,3451,6771,8001,971
−42.160.4265189
−3.2%3.5%12.8%8.7%
27.149.524.852.5
16.322.220.731.5
113123125125
−31.7−49.510.2208
−176−85155292
−14.7%−10.4%11.0%13.5%
−202−93.8138253
-28.72-13.3219.4735.85

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
14.114.114.114.1
2,4212,4242,4372,703
314248460500
444589659520
3,1933,2753,5693,737
1,4091,3241,3311,319
15413052115
0.2000
18515689.6289
1,4441,6652,0962,014
3,1933,2753,5693,737

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
−85.114−73.6
20350.4−241192
−81.3−1061841.9
36.4−41.9−64.5198
−44.3−22.6−137−123
−129−8.6−144−119
−28.3−0.2−0.3−0.4

Shareholding pattern

Source: NSE filings
70.2%
promoters
  • Promoters70.22%
  • Public29.78%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202670.22%29.78%0.00
30 Jun 202670.22%29.78%0.00
31 Mar 202670.22%29.78%0.00
31 Dec 202570.22%29.78%0.00
30 Sep 202570.22%29.78%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you